Cargando…

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma

Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also be...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauder, Michael C., Miller, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837322/
https://www.ncbi.nlm.nih.gov/pubmed/24281173
http://dx.doi.org/10.3390/cancers2031565
_version_ 1782292423289864192
author Stauder, Michael C.
Miller, Robert C.
author_facet Stauder, Michael C.
Miller, Robert C.
author_sort Stauder, Michael C.
collection PubMed
description Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also been shown to provide a benefit, but 5‑year overall survival still remains less than 5%. Conventional radiotherapy is traditionally delivered over a six week period and high toxicity is seen with the concomitant use of chemotherapy. In contrast, SBRT can be delivered in 3–5 days and, when used as a component of combined modality therapy with gemcitabine, disruption to the timely delivery of chemotherapy is minimal. Early single-institution reports of SBRT for unresectable pancreatic carcinoma demonstrate excellent local control with acceptable toxicity. Use of SBRT in unresectable pancreatic carcinoma warrants further investigation in order to improve the survival of patients with historically poor outcomes.
format Online
Article
Text
id pubmed-3837322
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38373222013-11-22 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma Stauder, Michael C. Miller, Robert C. Cancers (Basel) Review Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also been shown to provide a benefit, but 5‑year overall survival still remains less than 5%. Conventional radiotherapy is traditionally delivered over a six week period and high toxicity is seen with the concomitant use of chemotherapy. In contrast, SBRT can be delivered in 3–5 days and, when used as a component of combined modality therapy with gemcitabine, disruption to the timely delivery of chemotherapy is minimal. Early single-institution reports of SBRT for unresectable pancreatic carcinoma demonstrate excellent local control with acceptable toxicity. Use of SBRT in unresectable pancreatic carcinoma warrants further investigation in order to improve the survival of patients with historically poor outcomes. MDPI 2010-08-09 /pmc/articles/PMC3837322/ /pubmed/24281173 http://dx.doi.org/10.3390/cancers2031565 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Stauder, Michael C.
Miller, Robert C.
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
title Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
title_full Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
title_fullStr Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
title_full_unstemmed Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
title_short Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma
title_sort stereotactic body radiation therapy (sbrt) for unresectable pancreatic carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837322/
https://www.ncbi.nlm.nih.gov/pubmed/24281173
http://dx.doi.org/10.3390/cancers2031565
work_keys_str_mv AT staudermichaelc stereotacticbodyradiationtherapysbrtforunresectablepancreaticcarcinoma
AT millerrobertc stereotacticbodyradiationtherapysbrtforunresectablepancreaticcarcinoma